Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.

EJHaem·2022

Same author

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.

Leukemia·2020

Same author

Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2020

Same author

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Blood·2019

Same author

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.

Journal of hematology & oncology·2018

Same author

Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.

Acta haematologica·2017

Search research articles

Related Experiment Video

Updated: Apr 24, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Allogeneic stem cell transplantation for multiple myeloma.

William Bensinger¹

¹Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5-390, Seattle, WA 98109, USA.

Hematology/Oncology Clinics of North America

|September 13, 2014

Summary

Allogeneic stem cell transplantation (AlloSCT) shows mixed results for multiple myeloma, not yet a standard treatment. Future strategies focus on improving conditioning and preserving graft-versus-myeloma effects for better outcomes.

Keywords:

Allogeneic stem cell transplant Autologous stem cell transplant Multiple myeloma Myeloablative transplant Nonmyeloablative transplant Peripheral blood stem cells

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Apr 24, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Area of Science:

Hematology
Oncology
Immunotherapy

Background:

Tandem autologous stem cell transplantation (ASCT) and ASCT followed by allogeneic stem cell transplantation (AlloSCT) are treatment strategies for multiple myeloma.
Current prospective trials comparing these approaches yield inconclusive results regarding survival benefits.

Purpose of the Study:

To evaluate the efficacy of AlloSCT as a treatment for multiple myeloma.
To identify strategies for enhancing the effectiveness and safety of AlloSCT.

Main Methods:

Comparison of tandem ASCT versus ASCT followed by AlloSCT in prospective trials.
Review of existing literature on conditioning regimens and graft-versus-host disease modulation.

Main Results:

Progression-free and overall survival rates show mixed results between the two transplantation methods.
AlloSCT is not widely considered a standard treatment for multiple myeloma due to inconsistent outcomes.

Conclusions:

Improving the therapeutic index of conditioning regimens is crucial for better patient outcomes.
Modulating graft-versus-host disease while enhancing graft-versus-myeloma effects could establish AlloSCT as a mainstream treatment.
Investigational approaches like vaccines, monoclonal antibodies, and adoptive immunotherapies hold promise for advancing AlloSCT.